Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




Somatic Evolution Identified in Non-Neoplastic IBD-Affected Colon

By LabMedica International staff writers
Posted on 06 Aug 2020
Inflammatory bowel disease (IBD) is a debilitating disease characterized by repeated flares of intestinal inflammation. More...
The two major subtypes of IBD, Crohn’s disease (CD) and ulcerative colitis (UC) are distinguished by the location, continuity, and nature of the inflammatory lesions.

UC affects only the large intestine, spreading continuously from the distal to proximal colon, whereas CD most commonly affects the small and large intestine and is characterized by discontinuous bouts of inflammation. In addition to the significant morbidity associated with the disease, IBD patients have a 1.7-fold increased risk of developing gastrointestinal cancers compared to the general population.

A large team of scientists led by the Wellcome Sanger Institute (Hinxton, UK) whole-genome sequenced 446 colonic crypts from 46 IBD patients and compared these to 412 crypts from 41 non-IBD controls from a previous publication on the mutation landscape of the normal colon. Samples from the first 19 patients were whole genome sequenced on XTEN machines (Illumina, San Diego, CA, USA) and samples from other patients were whole genome sequenced on Illumina Htp NovaSeq 6000. Base substitution calling was carried out in four steps: Discovery, filtering of the discovery set, genotyping and filtering of the genotypes. Mutations were first called using the Cancer Variants through Expectation Maximization (CaVEMan) algorithm.

The investigators analyzed mutations in the colonic crypts in combination with information on IBD patients' age, the location of the tissue samples biopsied from the gut, and the extent of disease. Their search highlighted non-synonymous alterations affecting genes such as ARID1A, FBXW7, PIGR, ZC3H12A, and genes from the interleukin 17 and the Toll-like receptor pathways. Along with more extensive clonal expansions involving somatic mutations in samples from the IBD-affected individuals, the team noted that mutations tended to occur in genes that appear to be subject to positive selection in individuals with IBD.

Peter Campbell, MD, PhD, Head of Cancer Genetics and Genomics and co-senior author of the study, said, “These approaches have given us unique insights into the effects of inflammatory bowel disease on the DNA sequence of the inflamed tissue. The findings point to the possibility of using somatic alteration clues to understand IBD and other common diseases beyond cancer. It is exciting to see the methods that we and others have used to understand cancers now being applied to other common diseases.” The study was published on July 21, 2020 in the journal Cell.


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Integrated Biochemical & Immunological System
Biolumi CX8
New
Pan-Cancer Panel
TruSight Oncology 500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.